Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) Inc on Wednesday, setting a price target of $69, which is approximately 42.33% above the present share price of $48.48.
DeGeeter expects Ionis Pharmaceuticals Inc to post earnings per share (EPS) of -$0.23 for the fourth quarter of 2020.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Ionis Pharmaceuticals, with an average price target of $70.
The analysts price targets range from a high of $91 to a low of $54.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $145.54 million and a net profit of -$51.75 million. The company's market cap is $6.77 billion.
According to TipRanks.com, Oppenheimer analyst Kevin DeGeeter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 24.3% and a 48.55% success rate.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics (NASDAQ:AKCA) segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.